• Citer

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.

par Kim, Chungyeul;Tang, Gong;Pogue-Geile, Katherine L;Costantino, Joseph P;Baehner, Frederick L;Baker, Joffre;Cronin, Maureen T;Watson, Drew;Shak, Steven;Bohn, Olga L;Fumagalli, Debora ;Taniyama, Yusuke;Lee, Ahwon;Reilly, Megan L;Vogel, Victor G;McCaskill-Stevens, Worta;Ford, Leslie G;Geyer, Charles E;Wickerham, D Lawrence;Wolmark, Norman;Paik, Soonmyung
Référence Journal of clinical oncology, 29, 31, page (4160-4167)
Publication Publié, 2011-11

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Several mechanisms have been proposed to explain tamoxifen resistance of estrogen receptor (ER) -positive tumors, but a clinically useful explanation for such resistance has not been described. Because the ER is the treatment target for tamoxifen, a linear association between ER expression levels and the degree of benefit from tamoxifen might be expected. However, such an association has never been demonstrated with conventional clinical ER assays, and the ER is currently used clinically as a dichotomous marker. We used gene expression profiling and ER protein assays to help elucidate molecular mechanism(s) responsible for tamoxifen resistance in breast tumors.